

Elizabeth Garrett-Mayer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9435721/publications.pdf>

Version: 2024-02-01

207
papers

12,963
citations

29994

54
h-index

24915

109
g-index

215
all docs

215
docs citations

215
times ranked

18704
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. <i>JCO Oncology Practice</i> , 2022, 18, e426-e441. | 1.4 | 16 |
| 2 | Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 444-454. | 2.3 | 12 |
| 3 | Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 106-106. | 0.8 | 1 |
| 4 | Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 107-107. | 0.8 | 5 |
| 5 | Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. <i>JCO Oncology Practice</i> , 2022, , OP2100455. | 1.4 | 0 |
| 6 | Clinical Evidence Generation During a Pandemic. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 151-156. | 1.0 | 2 |
| 7 | Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts. <i>JCO Precision Oncology</i> , 2022, 6, e2100390. | 1.5 | 2 |
| 8 | Relationship Between Participation in ASCO's Quality Oncology Practice Initiative Program and American Board of Internal Medicine's Maintenance of Certification Program. <i>JCO Oncology Practice</i> , 2022, , OP2100777. | 1.4 | 0 |
| 9 | Defining comprehensive biomarker-related testing and treatment practices for advanced non-small cell lung cancer: Results of a survey of U.S. oncologists. <i>Cancer Medicine</i> , 2022, 11, 530-538. | 1.3 | 28 |
| 10 | Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient survey. <i>Cancer</i> , 2022, , . | 2.0 | 9 |
| 11 | Hematology/Oncology Fellowship Programs' Participation in the Quality Oncology Practice Initiative. <i>JCO Oncology Practice</i> , 2022, , OP2100807. | 1.4 | 0 |
| 12 | Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2022, 40, 2163-2171. | 0.8 | 68 |
| 13 | Sexual Orientation and Gender Identity Data Collection in Oncology Practice: Findings of an ASCO Survey. <i>JCO Oncology Practice</i> , 2022, 18, e1297-e1305. | 1.4 | 25 |
| 14 | Associations between biomarker testing and characteristics of patients with metastatic non-small cell lung cancer (mNSCLC): An analysis of CancerLinQ Discovery (CLQD) data.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9127-9127. | 0.8 | 0 |
| 15 | Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6530-6530. | 0.8 | 2 |
| 16 | Presentation, management, and outcome of COVID-19 among patients with cancer in the Middle East and North Africa (MENA) region.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18797-e18797. | 0.8 | 0 |
| 17 | Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3008-3008. | 0.8 | 7 |
| 18 | COVID-19 vaccine uptake in patients with cancer and Sars-Cov-2 infection in 2020: Results from the ASCO registry.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18713-e18713. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. Journal of Clinical Oncology, 2022, 40, 3114-3114. | 0.8 | 2 |
| 20 | Oncologistsâ€™ perspectives on individualizing dose selection for patients with metastatic cancer.. Journal of Clinical Oncology, 2022, 40, 1531-1531. | 0.8 | 0 |
| 21 | Breakthrough COVID-19 cases and hospitalization risk: ASCO COVID-19 registry.. Journal of Clinical Oncology, 2022, 40, e18807-e18807. | 0.8 | 0 |
| 22 | Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer. Clinical Breast Cancer, 2021, 21, 292-301. | 1.1 | 4 |
| 23 | A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer, 2021, 127, 894-904. | 2.0 | 12 |
| 24 | Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clinical Cancer Research, 2021, 27, 2424-2429. | 3.2 | 35 |
| 25 | Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends of Cancer Recommendations. Clinical Cancer Research, 2021, 27, 2430-2434. | 3.2 | 28 |
| 26 | Identification of Transgender People With Cancer in Electronic Health Records: Recommendations Based on CancerLinQ Observations. JCO Oncology Practice, 2021, 17, e336-e342. | 1.4 | 7 |
| 27 | A Bayesian Phase I/II Design for Cancer Clinical Trials Combining an Immunotherapeutic Agent with a Chemotherapeutic Agent. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 1210-1229. | 0.5 | 3 |
| 28 | Challenges and opportunities to developing a frailty index using electronic health record data. Journal of Geriatric Oncology, 2021, 12, 851-854. | 0.5 | 7 |
| 29 | Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. JCO Oncology Practice, 2021, 17, e999-e1011. | 1.4 | 3 |
| 30 | Abstract CT173: Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) with FGFR1 mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. , 2021, , . | | 2 |
| 31 | A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clinical Cancer Research, 2021, 27, 5472-5481. | 3.2 | 4 |
| 32 | Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. Journal of Clinical Oncology, 2021, 39, 2720-2731. | 0.8 | 52 |
| 33 | Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology, 2021, 39, 2443-2451. | 0.8 | 97 |
| 34 | Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Reports Medicine, 2021, 2, 100426. | 3.3 | 28 |
| 35 | Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. Journal of Clinical Oncology, 2020, 38, 480-487. | 0.8 | 3 |
| 36 | Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology, 2020, 15, 743-750. | 1.7 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Development and implementation of the SUM breast cancer cell line functional genomics knowledge base. <i>Npj Breast Cancer</i> , 2020, 6, 30. | 2.3 | 4 |
| 38 | Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. <i>Targeted Oncology</i> , 2020, 15, 733-741. | 1.7 | 25 |
| 39 | To Treat or Not to Treat—Balancing Benefits and Risks of Treatment Delay Among Patients With Cancer During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1868. | 3.4 | 6 |
| 40 | Palbociclib in Patients With Non—Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2020, 4, 757-766. | 1.5 | 52 |
| 41 | Geographically distributed data should be analyzed with spatial epidemiologic methods. <i>Cancer</i> , 2020, 126, 1161-1162. | 2.0 | 1 |
| 42 | Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab. <i>Clinical Cancer Research</i> , 2020, 26, 3280-3286. | 3.2 | 28 |
| 43 | Nicotine replacement therapy sampling for smoking cessation within primary care: results from a pragmatic cluster randomized clinical trial. <i>Addiction</i> , 2020, 115, 1358-1367. | 1.7 | 31 |
| 44 | Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4637-4637. | 0.8 | 9 |
| 45 | Vital status ascertainment in cancerlinq discovery (CLQD): Improvement in mortality capture with a supplemental data source.. <i>Journal of Clinical Oncology</i> , 2020, 38, 7064-7064. | 0.8 | 3 |
| 46 | Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with <i>BRAF</i> V600E mutations: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 122-122. | 0.8 | 10 |
| 47 | Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with <i>ERBB2</i> amplification or overexpression: Results from the TAPUR Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 132-132. | 0.8 | 38 |
| 48 | Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 133-133. | 0.8 | 28 |
| 49 | Annual trends in opioid prescribing for patients (Pts) with metastatic non-small cell lung cancer (mNSCLC): Cancerlinq data analysis, 2010 to 2017.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2076-2076. | 0.8 | 0 |
| 50 | Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5567-5567. | 0.8 | 2 |
| 51 | Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19311-e19311. | 0.8 | 1 |
| 52 | NGS testing use and results: A survey of U.S. oncologists.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19145-e19145. | 0.8 | 1 |
| 53 | Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19046-e19046. | 0.8 | 0 |
| 54 | Biosimilar usage in practices within the ASCO PracticeNET learning network.. <i>Journal of Clinical Oncology</i> , 2020, 38, 77-77. | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Molecular properties of gp100-reactive T cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 68-78. | 1.5 | 9 |
| 56 | Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. <i>Journal of Clinical Oncology</i> , 2019, 37, 336-349. | 0.8 | 101 |
| 57 | Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer. <i>JAMA Network Open</i> , 2019, 2, e191703. | 2.8 | 47 |
| 58 | Delivery of TRAIL-expressing plasmid DNA to cancer cells <i>in vitro</i> and <i>in vivo</i> using aminoglycoside-derived polymers. <i>Journal of Materials Chemistry B</i> , 2019, 7, 7014-7025. | 2.9 | 11 |
| 59 | Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors. <i>Journal of Oncology Practice</i> , 2019, 15, e1050-e1065. | 2.5 | 3 |
| 60 | Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-8. | 1.5 | 46 |
| 61 | Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 118-128. | 3.0 | 49 |
| 62 | Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 559-571. | 1.1 | 36 |
| 63 | Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1014-1014. | 0.8 | 29 |
| 64 | Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9041-9041. | 0.8 | 7 |
| 65 | Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, LBA108-LBA108. | 0.8 | 10 |
| 66 | Utilizing visualization to qualitatively evaluate electronic health record-derived database limitations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 317-317. | 0.8 | 1 |
| 67 | Hypertension and use of bevacizumab among patients treated in community settings.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18279-e18279. | 0.8 | 0 |
| 68 | Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2019, 37, 11008-11008. | 0.8 | 0 |
| 69 | Effectiveness of ASCO's adverse event reporting decision aid: Results from an interventional study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3065-3065. | 0.8 | 0 |
| 70 | Visualizing treatment patterns and survival in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 316-316. | 0.8 | 1 |
| 71 | Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells. <i>Cancer Research</i> , 2018, 78, 3067-3074. | 0.4 | 6 |
| 72 | ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 694-704. | 5.1 | 310 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 691-702. | 2.0 | 30 |
| 74 | Altered Peptide Ligands Impact the Diversity of Polyfunctional Phenotypes in T Cell Receptor Gene-Modified T Cells. <i>Molecular Therapy</i> , 2018, 26, 996-1007. | 3.7 | 8 |
| 75 | Ceramide Synthase 6 Deficiency Enhances Inflammation in the DSS model of Colitis. <i>Scientific Reports</i> , 2018, 8, 1627. | 1.6 | 28 |
| 76 | TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence. <i>Journal of Leukocyte Biology</i> , 2018, 103, 973-983. | 1.5 | 9 |
| 77 | Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy. <i>Journal of Computer Assisted Tomography</i> , 2018, 42, 146-150. | 0.5 | 5 |
| 78 | A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2018, 94, 329-339. | 0.9 | 36 |
| 79 | Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 311-325. | 2.0 | 40 |
| 80 | CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. <i>Cell Metabolism</i> , 2018, 27, 85-100.e8. | 7.2 | 197 |
| 81 | Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14. | 1.5 | 98 |
| 82 | The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. <i>Journal of Oncology Practice</i> , 2018, 14, e412-e420. | 2.5 | 114 |
| 83 | Understanding the Role of Advanced Practice Providers in Oncology in the United States. <i>Journal of Oncology Practice</i> , 2018, 14, e518-e532. | 2.5 | 48 |
| 84 | State Tobacco Policies as Predictors of Evidence-Based Cessation Method Usage: Results From a Large, Nationally Representative Dataset. <i>Nicotine and Tobacco Research</i> , 2018, 20, 1336-1343. | 1.4 | 10 |
| 85 | Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models. <i>BMC Cancer</i> , 2018, 18, 1233. | 1.1 | 7 |
| 86 | The effect of bone marrow graft composition on pediatric bone marrow transplantation outcomes. <i>Pediatric Transplantation</i> , 2018, 22, e13287. | 0.5 | 2 |
| 87 | The Evolution of Phase I Trials, Past, Present, and Future. , 2018, , 17-32. | | 1 |
| 88 | An Adaptive Dose-Finding Design Based on Both Safety and Immunologic Responses in Cancer Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2018, 10, 185-195. | 0.6 | 11 |
| 89 | Preoperative predictors of occult nodal disease in cT1N0 oral cavity squamous cell carcinoma: Review of 2623 cases. <i>Head and Neck</i> , 2018, 40, 1967-1976. | 0.9 | 22 |
| 90 | Nicotine replacement therapy sampling via primary care: Methods from a pragmatic cluster randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2018, 72, 1-7. | 0.8 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2532-2532. | 0.8 | 27 |
| 92 | Attributable failure and costs associated with continued smoking by cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1559-1559. | 0.8 | 0 |
| 93 | Understanding the Role of Advanced Practice Providers in Oncology in the United States. <i>Journal of the Advanced Practitioner in Oncology</i> , 2018, 9, 585-598. | 0.2 | 7 |
| 94 | Adherence to National Comprehensive Cancer Network guidelines for time to initiation of postoperative radiation therapy for patients with head and neck cancer. <i>Cancer</i> , 2017, 123, 2651-2660. | 2.0 | 83 |
| 95 | Effect of postoperative radiotherapy on survival for surgically managed pT3N0 and pT4aN0 laryngeal cancer: Analysis of the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 2248-2257. | 2.0 | 17 |
| 96 | Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 82. | 6.9 | 105 |
| 97 | CD8, FoxP3, and CD45RO+ Lymphocytic Infiltrates in Type I and Type II Endometrial Cancers in African American and European American Females. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 540-549. | 0.9 | 5 |
| 98 | A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4642-4650. | 3.2 | 124 |
| 99 | Platelets subvert T cell immunity against cancer via GARP-TGF β axis. <i>Science Immunology</i> , 2017, 2, . | 5.6 | 237 |
| 100 | Snus undermines quit attempts but not abstinence: a randomised clinical trial among US smokers. <i>Tobacco Control</i> , 2017, 26, 202-209. | 1.8 | 15 |
| 101 | Alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 can support immune responses toward tumors overexpressing ganglioside D3 in mice. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 63-75. | 2.0 | 4 |
| 102 | Critical biological parameters modulate affinity as a determinant of function in T-cell receptor gene-modified T-cells. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1411-1424. | 2.0 | 15 |
| 103 | HCV T Cell Receptor Chain Modifications to Enhance Expression, Pairing, and Antigen Recognition in T Cells for Adoptive Transfer. <i>Molecular Therapy - Oncolytics</i> , 2017, 5, 105-115. | 2.0 | 17 |
| 104 | Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 737-751. | 2.0 | 7 |
| 105 | The differential impact of state tobacco control policies on cessation treatment utilization across established tobacco disparities groups. <i>Preventive Medicine</i> , 2017, 105, 319-325. | 1.6 | 5 |
| 106 | Bone mineral density during pregnancy in women participating in a randomized controlled trial of vitamin D supplementation. <i>American Journal of Clinical Nutrition</i> , 2017, 106, 1422-1430. | 2.2 | 18 |
| 107 | Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer. <i>Cancer</i> , 2017, 123, 4841-4850. | 2.0 | 107 |
| 108 | Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis. <i>Scientific Reports</i> , 2017, 7, 15552. | 1.6 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Smoking status and symptom burden in surgical head and neck cancer patients. <i>Laryngoscope</i> , 2017, 127, 127-133. | 1.1 | 28 |
| 110 | Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 751-758. | 0.8 | 110 |
| 111 | Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. <i>Journal of Clinical Oncology</i> , 2017, 35, 3737-3744. | 0.8 | 331 |
| 112 | The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer. <i>Oncotarget</i> , 2017, 8, 22991-23007. | 0.8 | 24 |
| 113 | Abstract A50: An exploratory study examining the acute phase impact of resection on biological and psychological markers of stress among early stage non-small cell lung cancer patients. , 2017, , . | | 0 |
| 114 | Defining adverse events of anti-programmed-death-1 (Anti-PD1) agents using FDA adverse event reporting system (FAERS).. <i>Journal of Clinical Oncology</i> , 2017, 35, e14568-e14568. | 0.8 | 0 |
| 115 | Abstract 5474: Sphingosine kinase 2/sphingosine 1-phosphate signaling regulates p16 mediated accelerated aging in normal somatic tissues and tcf21 mediated tumor suppression in lung cancer. , 2017, , . | | 0 |
| 116 | Surface Expression of TGF β 2 Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer. <i>Cancer Research</i> , 2016, 76, 7106-7117. | 0.4 | 76 |
| 117 | Relationship of ABO Incompatible HSCT to Outcomes in Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S247. | 2.0 | 0 |
| 118 | Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. <i>Journal of Leukocyte Biology</i> , 2016, 100, 545-557. | 1.5 | 15 |
| 119 | Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. <i>Cancer Research</i> , 2016, 76, 6006-6016. | 0.4 | 56 |
| 120 | Association of <i>BRCA1</i> Mutations with Impaired Ovarian Reserve: Connection Between Infertility and Breast/Ovarian Cancer Risk. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 337-343. | 0.7 | 53 |
| 121 | A longitudinal, naturalistic study of U.S. smokers' trial and adoption of snus. <i>Addictive Behaviors</i> , 2016, 63, 82-88. | 1.7 | 8 |
| 122 | One-Year Smoking Trajectories Among Established Adult Smokers With Low Baseline Motivation to Quit. <i>Nicotine and Tobacco Research</i> , 2016, 20, ntw264. | 1.4 | 5 |
| 123 | Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases?. <i>Gynecologic Oncology</i> , 2016, 142, 278-282. | 0.6 | 18 |
| 124 | The Effect of Bone Marrow Graft Composition on Pediatric Bone Marrow Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S247-S248. | 2.0 | 0 |
| 125 | TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 293-304. | 2.0 | 41 |
| 126 | Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control. <i>Oncotarget</i> , 2016, 7, 69371-69383. | 0.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. <i>Oncotarget</i> , 2016, 7, 36138-36153. | 0.8 | 6 |
| 128 | Reduction in promotor methylation utilizing EGCG (epigallocatechin-3-gallate) restores RXR β expression in human colon cancer cells. <i>Oncotarget</i> , 2016, 7, 35313-35326. | 0.8 | 53 |
| 129 | A feasibility and safety study of vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with advanced pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14579-e14579. | 0.8 | 0 |
| 130 | Evaluating the reliability of the Attitudes to Randomized Trial Questionnaire (ARTQ) in a predominantly African American sample. <i>SpringerPlus</i> , 2015, 4, 411. | 1.2 | 4 |
| 131 | A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs. <i>Clinical Trials</i> , 2015, 12, 24-33. | 0.7 | 5 |
| 132 | Binding of the sphingolipid S1P to hTERT stabilizes telomerase at the nuclear periphery by allosterically mimicking protein phosphorylation. <i>Science Signaling</i> , 2015, 8, ra58. | 1.6 | 114 |
| 133 | The Faculty Costs to Educate a Biomedical Sciences Graduate Student. <i>CBE Life Sciences Education</i> , 2015, 14, ar3. | 1.1 | 4 |
| 134 | The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2744-2752. | 1.9 | 82 |
| 135 | IL-2 β mediates temporal regulation of IL-2 signaling and enhances immunotherapy. <i>Science Translational Medicine</i> , 2015, 7, 311ra170. | 5.8 | 49 |
| 136 | Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner. <i>Journal of Biological Chemistry</i> , 2015, 290, 13157-13167. | 1.6 | 31 |
| 137 | Effector CD8 $^+$ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7R β Dependent. <i>Cancer Immunology Research</i> , 2015, 3, 1364-1374. | 1.6 | 26 |
| 138 | Oncogenic signaling in amphiregulin and EGFR α -expressing PTEN α -null human breast cancer. <i>Molecular Oncology</i> , 2015, 9, 527-543. | 2.1 | 24 |
| 139 | Cervical esophageal cancer: A population α -based study. <i>Head and Neck</i> , 2015, 37, 808-814. | 0.9 | 59 |
| 140 | Abstract CT122: RCT of an herbal mouthrinse for radiotherapy induced oral mucositis in cancer patients. , 2015, , . | | 0 |
| 141 | Incorporating Patient Satisfaction Metrics in Assessing Multidisciplinary Breast Cancer Care Quality. <i>Southern Medical Journal</i> , 2015, 108, 372-6. | 0.3 | 7 |
| 142 | KAT6A, a Chromatin Modifier from the 8p11-p12 Amplicon is a Candidate Oncogene in Luminal Breast Cancer. <i>Neoplasia</i> , 2014, 16, 644-655. | 2.3 | 37 |
| 143 | Affective Motives for Smoking Among Early Stage Smokers. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1387-1393. | 1.4 | 11 |
| 144 | A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF α -Secreting Breast Tumor Vaccine for HER2 $^+$ Metastatic Breast Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 949-961. | 1.6 | 77 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Promoting Thiol Expression Increases the Durability of Antitumor T-cell Functions. <i>Cancer Research</i> , 2014, 74, 6036-6047. | 0.4 | 34 |
| 146 | Dynamics of tissue shrinkage during ablative temperature exposures. <i>Physiological Measurement</i> , 2014, 35, 55-67. | 1.2 | 69 |
| 147 | Polymer-enhanced delivery increases adenoviral gene expression in an orthotopic model of bladder cancer. <i>Journal of Controlled Release</i> , 2014, 176, 35-43. | 4.8 | 20 |
| 148 | American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 1277-1280. | 0.8 | 354 |
| 149 | Phase 2 Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 837-844. | 0.4 | 45 |
| 150 | SPECT Analysis of Cardiac Perfusion Changes After Whole-Breast/Chest Wall Radiation Therapy With or Without Active Breathing Coordinator: Results of a Randomized Phase 3 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 778-785. | 0.4 | 70 |
| 151 | Regulation of the Tumor Suppressor FOXO3 by the Thromboxane-A2 Receptors in Urothelial Cancer. <i>PLoS ONE</i> , 2014, 9, e107530. | 1.1 | 14 |
| 152 | Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. <i>Oncoscience</i> , 2014, 1, 522-528. | 0.9 | 24 |
| 153 | Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A α ERIPK1 α -dependent necroptosis. <i>EMBO Molecular Medicine</i> , 2013, 5, 105-121. | 3.3 | 217 |
| 154 | Mutant HSP70 Reverses Autoimmune Depigmentation in Vitiligo. <i>Science Translational Medicine</i> , 2013, 5, 174ra28. | 5.8 | 100 |
| 155 | Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. <i>Haematologica</i> , 2012, 97, 1736-1742. | 1.7 | 65 |
| 156 | Vitamin D3 supplementation (4000 IU/d for 1 y) eliminates differences in circulating 25-hydroxyvitamin D between African American and white men. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 332-336. | 2.2 | 28 |
| 157 | Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method. <i>Clinical Trials</i> , 2012, 9, 303-313. | 0.7 | 37 |
| 158 | A Coreceptor-Independent Transgenic Human TCR Mediates Anti-Tumor and Anti-Self Immunity in Mice. <i>Journal of Immunology</i> , 2012, 189, 1627-1638. | 0.4 | 44 |
| 159 | Vitamin D ³ Supplementation at 4000 International Units Per Day for One Year Results in a Decrease of Positive Cores at Repeat Biopsy in Subjects with Low-Risk Prostate Cancer under Active Surveillance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2315-2324. | 1.8 | 112 |
| 160 | Latent Class Analysis. , 2012, , 700-707. | | 0 |
| 161 | ZEB1-responsive genes in non-small cell lung cancer. <i>Cancer Letters</i> , 2011, 300, 66-78. | 3.2 | 147 |
| 162 | A Novel Extracellular Hsp90 Mediated Co-Receptor Function for LRP1 Regulates EphA2 Dependent Glioblastoma Cell Invasion. <i>PLoS ONE</i> , 2011, 6, e17649. | 1.1 | 113 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Using Endobronchial Ultrasound Features to Predict Lymph Node Metastasis in Patients With Lung Cancer. <i>Chest</i> , 2011, 140, 1550-1556. | 0.4 | 91 |
| 164 | Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading. <i>Statistics in Medicine</i> , 2011, 30, 2070-2080. | 0.8 | 43 |
| 165 | Incorporating scientific knowledge into phenotype development: Penalized latent class regression. <i>Statistics in Medicine</i> , 2011, 30, 784-798. | 0.8 | 4 |
| 166 | Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , 2010, 16, 1726-1736. | 3.2 | 152 |
| 167 | K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate. <i>Clinical Cancer Research</i> , 2010, 16, 338-347. | 3.2 | 106 |
| 168 | Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 203-211. | 3.2 | 186 |
| 169 | Randomized Phase II Study of Two Schedules of Flavopiridol (Alvocidib, F) Given as Timed Sequential Therapy (TST) With Ara-C and Mitoxantrone (FLAM) for Adults with Newly Diagnosed, Poor-Risk Acute Myelogenous Leukemia (AML). <i>Blood</i> , 2010, 116, 186-186. | 0.6 | 2 |
| 170 | Adolescent nondaily smokers: Favorable views of tobacco yet receptive to cessation. <i>Nicotine and Tobacco Research</i> , 2009, 11, 348-355. | 1.4 | 24 |
| 171 | Modified test statistics by inter-voxel variance shrinkage with an application to f MRI. <i>Biostatistics</i> , 2009, 10, 219-227. | 0.9 | 10 |
| 172 | Dose-finding study of ¹⁵³ Sm-EDTMP in patients with poor-prognosis osteosarcoma. <i>Cancer</i> , 2009, 115, 2514-2522. | 2.0 | 55 |
| 173 | Repeatable battery for assessment of neuropsychological status in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1453-1460. | 2.2 | 20 |
| 174 | Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 49-59. | 2.0 | 1,089 |
| 175 | Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. <i>Blood</i> , 2009, 113, 4841-4852. | 0.6 | 54 |
| 176 | Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 97-107. | 3.2 | 163 |
| 177 | Effect of DNA Methylation on Identification of Aggressive Prostate Cancer. <i>Urology</i> , 2008, 72, 1234-1239. | 0.5 | 46 |
| 178 | Tamoxifen-stimulated growth of breast cancer due to p21 loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 288-293. | 3.3 | 86 |
| 179 | Pharmacodynamic-Guided Modified Continuous Reassessment Method-Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 4172-4179. | 0.8 | 63 |
| 180 | Novel Role of Thromboxane Receptors β^2 Isoform in Bladder Cancer Pathogenesis. <i>Cancer Research</i> , 2008, 68, 4097-4104. | 0.4 | 60 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 181 | Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. <i>Anti-Cancer Drugs</i> , 2008, 19, 1007-1011. | 0.7 | 0 |
| 182 | How Should Treatment Decisions Be Made for Incapacitated Patients, and Why?. <i>PLoS Medicine</i> , 2007, 4, e35. | 3.9 | 34 |
| 183 | Social and Communication Development in Toddlers With Early and Later Diagnosis of Autism Spectrum Disorders. <i>Archives of General Psychiatry</i> , 2007, 64, 853. | 13.8 | 453 |
| 184 | Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3965-3970. | 0.8 | 257 |
| 185 | A Prostate-Specific Antigen-Activated Channel-Forming Toxin as Therapy for Prostatic Disease. <i>Journal of the National Cancer Institute</i> , 2007, 99, 376-385. | 3.0 | 84 |
| 186 | Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. <i>Carcinogenesis</i> , 2007, 28, 1485-1490. | 1.3 | 283 |
| 187 | Cross-study validation and combined analysis of gene expression microarray data. <i>Biostatistics</i> , 2007, 9, 333-354. | 0.9 | 46 |
| 188 | A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. <i>Blood</i> , 2007, 109, 1387-1394. | 0.6 | 180 |
| 189 | Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1185-1191. | 2.0 | 24 |
| 190 | Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. <i>Gynecologic Oncology</i> , 2007, 106, 82-88. | 0.6 | 77 |
| 191 | Response to Joint Attention in Toddlers at Risk for Autism Spectrum Disorder: A Prospective Study. <i>Journal of Autism and Developmental Disorders</i> , 2007, 37, 37-48. | 1.7 | 205 |
| 192 | The continual reassessment method for dose-finding studies: a tutorial. <i>Clinical Trials</i> , 2006, 3, 57-71. | 0.7 | 165 |
| 193 | Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin's Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 965-972. | 2.0 | 44 |
| 194 | The Accuracy of Surrogate Decision Makers. <i>Archives of Internal Medicine</i> , 2006, 166, 493. | 4.3 | 796 |
| 195 | Development in infants with autism spectrum disorders: a prospective study. <i>Journal of Child Psychology and Psychiatry and Allied Disciplines</i> , 2006, 47, 629-638. | 3.1 | 569 |
| 196 | Prevalence and determinants of physician bedside rationing. <i>Journal of General Internal Medicine</i> , 2006, 21, 1138-1143. | 1.3 | 99 |
| 197 | Epigenetic suppression of secreted frizzled related protein 1 (SFRP1) expression in human breast cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 281-286. | 1.5 | 81 |
| 198 | Quantitative Multiplex Methylation-Specific PCR Analysis Doubles Detection of Tumor Cells in Breast Ductal Fluid. <i>Clinical Cancer Research</i> , 2006, 12, 3306-3310. | 3.2 | 122 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Ductal Access for Prevention and Therapy of Mammary Tumors. <i>Cancer Research</i> , 2006, 66, 638-645. | 0.4 | 84 |
| 200 | Does It Pay to Pay?. <i>Nursing Research</i> , 2005, 54, 178-183. | 0.8 | 51 |
| 201 | Pharmacologic and Toxicologic Evaluation of <i>C. novyi-NT</i> Spores. <i>Toxicological Sciences</i> , 2005, 88, 562-575. | 1.4 | 90 |
| 202 | Very High Frequency of Hypermethylated Genes in Breast Cancer Metastasis to the Bone, Brain, and Lung. <i>Clinical Cancer Research</i> , 2004, 10, 3104-3109. | 3.2 | 129 |
| 203 | Gene expression alterations over large chromosomal regions in cancers include multiple genes unrelated to malignant progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8715-8720. | 3.3 | 49 |
| 204 | Response to letters on B-readers study. <i>Academic Radiology</i> , 2004, 11, 1402-1404. | 1.3 | 0 |
| 205 | Comparison of B-readers' interpretations of chest radiographs for asbestos related changes. <i>Academic Radiology</i> , 2004, 11, 843-856. | 1.3 | 39 |
| 206 | Eliminating catheter-related bloodstream infections in the intensive care unit*. <i>Critical Care Medicine</i> , 2004, 32, 2014-2020. | 0.4 | 996 |
| 207 | Models for Probability of Under- and Overexpression: The POE Scale. , 0, , 137-154. | | 2 |